Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review)
- Authors:
- Qianqian Zhao
- Kun He
- Xiuhua Zhang
- Mingjie Xu
- Xiuping Zhang
- Huanjie Li
-
Affiliations: Microbiology Department, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250013, P.R. China, Key Laboratory of Biological Drugs, Shandong Academy of Pharmaceutical Science, Jinan, Shandong 250101, P.R. China, Medical Research and Laboratory Diagnostic Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250013, P.R. China - Published online on: May 30, 2022 https://doi.org/10.3892/etm.2022.11401
- Article Number: 474
-
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Duncan JD, Urbanowicz RA, Tarr AW and Ball JK: Hepatitis C Virus vaccine: Challenges and prospects. Vaccines (Basel). 8(90)2020.PubMed/NCBI View Article : Google Scholar | |
|
Ramsay J, Marsh J, Pedrana A, Andric N, Norman R, Cheng W, Webb S, Zeps N, Bellgard M, Graves T, et al: A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): Protocol for a prospective treatment registry of real-world outcomes for hepatitis C. BMC Infect Dis. 20(802)2020.PubMed/NCBI View Article : Google Scholar | |
|
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB and Sulkowski MS: Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review. Ann Intern Med. 166:637–648. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Li D, Huang Z and Zhong J: Hepatitis C virus vaccine development: Old challenges and new opportunities. Natl Sci Rev. 2:285–295. 2015. | |
|
Forns X, Bukh J and Purcell RH: The challenge of developing a vaccine against hepatitis C virus. J Hepatol. 37:684–695. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Buonaguro L, Tagliamonte M, Tornesello ML and Buonaguro FM: Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines. 10:1569–1583. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ and Liang TJ: Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus vaccinia infection. Proc Natl Acad Sci USA. 100:6753–6758. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Christiansen D, Earnest-Silveira L, Grubor-Bauk B, Wijesundara DK, Boo I, Ramsland PA, Vincan E, Drummer HE, Gowans EJ and Torresi J: Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci Rep. 9(9251)2019.PubMed/NCBI View Article : Google Scholar | |
|
Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, Yeager M and Chisari FV: Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol. 84:10999–11009. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Matsuura Y, Harada S, Suzuki R, Watanabe Y, Inoue Y, Saito I and Miyamura T: Expression of processed envelope protein of hepatitis C virus in mammalian and insect cells. J Virol. 66:1425–1431. 1992.PubMed/NCBI View Article : Google Scholar | |
|
Baumert TF, Ito S, Wong DT and Liang TJ: Hepatitis C virus structural proteins assemble into virus like particles in insect cells. J Virol. 72:3827–3836. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Mihailova M, Boos M, Petrovskis I, Ose V, Skrastina D, Fiedler M, Sominskaya I, Ross S, Pumpens P, Roggendorf M and Viazov S: Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine. 24:4369–4377. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Beaumont E, Patient R, Hourioux C, Dimier-Poisson I and Roingeard P: Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology. 57:1303–1313. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bedard MC, Simard S, Lecours K, Bolduc M, Pare C, Willems B, et al: Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: Evidence for the critical function of multimerization. Virology. 363:59–68. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Chua BY, Johnson D, Tan A, Earnest-Silveira L, Sekiya T, Chin R, Torresi J and Jackson DC: Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One. 7(e47492)2012.PubMed/NCBI View Article : Google Scholar | |
|
Qiao M, Murata K, Davis AR, Jeong SH and Liang TJ: Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology. 37:52–59. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Acosta-Rivero N, Poutou J, Alvarez-Lajonchere L, Guerra I, Aguilera Y, Musacchio A, Rodríguez A, Aguilar JC, Falcon V, Alvarez-Obregon JC, et al: Recombinant in vitro assembled hepatitis C virus core particles induce strong specific immunity enhanced by formulation with an oil-based adjuvant. Biol Res. 42:41–56. 2009.PubMed/NCBI | |
|
Logan M, Law J, Wong JAJ, Hockman D, Landi A, Chen C, Crawford K, Kundu J, Baldwin L, Johnson J, et al: Native folding of a recombinant gpE1/gpE2 heterodimer vaccine antigen from a precursor protein fused with Fc IgG. J Virol. 91:e01552–16. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Krapchev VB, Rychlowska M, Chmielewska A, Zimmer K, Patel AH and Bienkowska-Szewczyk K: Recombinant flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice. Virology. 519:33–41. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH and Ball JK: Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol. 80:8695–8704. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Tzarum N, Wilson IA and Law M: The neutralizing face of hepatitis C Virus E2 envelope glycoprotein. Front Immunol. 9(1315)2018.PubMed/NCBI View Article : Google Scholar | |
|
Kumar A, Hossain RA, Yost SA, Bu W, Wang Y, Dearborn AD, Grakoui A, Cohen JI and Marcotrigiano J: Structural insights into hepatitis C virus receptor binding and entry. Nature. 598:521–525. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, Mckeating JA, Leroux-Roels G, et al: Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. Hepatology. 63:1120–1134. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Wang Y, Keck ZY and Foung SK: Neutralizing antibody response to hepatitis C virus. Viruses. 3:2127–2145. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Keck ZY, Saha A, Xia J, Wang Y, Lau P, Krey T, Rey FA and Foung SK: Mapping a region of HCV E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J Virol. 85:10451–10463. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Guest JD and Pierce BG: Structure-based and rational design of a hepatitis C Virus vaccine. Viruses. 13(837)2021.PubMed/NCBI View Article : Google Scholar | |
|
Pierce BG, Keck ZY, Wang R, Lau P, Garagusi K, Elkholy K, Toth EA, Urbanowicz RA, Guest JD, Agnihotri P, et al: Structure-based design of hepatitis C Virus E2 glycoprotein improves serum binding and cross-neutralization. J Virol. 94:e00704–20. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Kachko A, Frey SE, Sirota L, Ray R, Wells F, Zubkova I, Zhang P and Major ME: Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity. Hepatology. 62:1670–1682. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, Mihalik K, Virata ML, Alter HJ, Feinstone S and Major M: Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci USA. 106:7537–7541. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Ruwona TB, Giang E, Nieusma T and Law M: Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. J Virol. 88:10459–10471. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Vietheer PT, Boo I, Gu J, McCaffrey K, Edwards S, Owczarek C, Hardy MP, Fabri L, Center RJ, Poumbourios P and Drummer HE: The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Hepatology. 65:1117–1131. 2017.PubMed/NCBI View Article : Google Scholar | |
|
McCaffrey K, Boo I, Owczarek CM, Hardy MP, Perugini MA, Fabri L, Scotney P, Poumbourios P and Drummer HE: An optimized hepatitis C virus E2 glycoprotein core adopts a functional homodimer that effciently blocks virus entry. J Virol. 91:e01668–16. 2017.PubMed/NCBI View Article : Google Scholar | |
|
McCaffrey K, Boo I, Poumbourios P and Drummer HE: Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding. J Virol. 81:9584–9590. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Li D, von Schaewen M, Wang X, Tao W, Zhang Y, Li L, Heller B, Hrebikova G, Deng Q, Ploss A, et al: Altered glycosylation patterns increase immunogenicity of a subunit hepatitis C virus vaccine, inducing neutralizing antibodies which confer protection in mice. J Virol. 90:10486–10498. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Urbanowicz RA, Wang R, Schiel JE, Keck ZY, Kerzic MC, Lau P, Rangarajan S, Garagusi KJ, Tan L, Guest JD, et al: Antigenicity and immunogenicity of differentially glycosylated hepatitis C virus E2 envelope proteins expressed in mammalian and insect Cells. J Virol. 93:e01403–18. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Naarding MA, Falkowska E, Xiao H and Dragic T: Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice. Vaccine. 29:2910–2917. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, et al: Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine. 28:6367–6373. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M, Zeuzem S, et al: Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine. 27:5142–5151. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Sarobe P, Pendieton CD, Akatsuka T, Lau D, Engelhard VH, Feinstone SM and Berzofsky JA: Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest. 102:1239–1248. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Filskov J, Mikkelsen M, Hansen PR, Christensen JP, Thomsen AR, Andersen P, Bukh J and Agger EM: Broadening CD4+ and CD8+ T cell responses against hepatitis C virus by vaccination with NS3 overlapping peptide panels in cross-priming liposomes. J Virol. 91:e00130–17. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Filskov J, Andersen P, Agger EM and Bukh J: HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen. Sci Rep. 9(14085)2019.PubMed/NCBI View Article : Google Scholar | |
|
Firbas C, Boehm T, Buerger V, Schuller E, Sabarth N, Jilma B and Klade CS: Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. Vaccine. 28:2397–2407. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J and Klade CS: Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine. 24:4343–4353. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, et al: Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology. 134:1385–1395. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Yin D, Qi ZT, Yan S, Ding H, Hua X, Tong YM, Wang YZ, Liu Y, Xu FH and Zhao P: Study on the induction of mouse neutralization antibodies to HCVpp by HCV E2 DNA vaccines. Chin J Exp Clin Infect Dis (Electronic Version). 2:24–32. 2008.(In Chinese). | |
|
National Institute of Allergy and Infectious Diseases (NIH): Trial Evaluating Experimental Hepatitis C Vaccine Concludes. NIH, Bethesda, MD, 2019. https://www.niaid.nih.gov/news-events/trial-evaluating-experimental-hepatitis-c-vaccine-concludes. Accessed July 8, 2021. | |
|
Shin EC, Sung PS and Park SH: Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 16:509–523. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Lu L, Barbi J and Pan F: The regulation of immune tolerance by FOXP3. Nat Rev Immunol. 17:703–717. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Langhans B, Nischalke HD, Krämer B, Hausen A, Dold L, van Heteren P, Hüneburg R, Nattermann J, Strassburg CP and Spengler U: Increased peripheral CD4+ regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. J Hepatol. 66:888–896. 2017.PubMed/NCBI View Article : Google Scholar : (In Albanian, English). | |
|
Han JW, Sung PS, Hong SH, Lee H, Koh JY, Lee H, White S, Maslow JN, Weiner DB, Park SH, et al: IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses. J Hepatol. 73:72–83. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Wijesundara DK, Gummow J, Li Y, Yu W, Quah BJ, Ranasinghe C, Torresi J, Gowans EJ and Grubor-Bauk B: Induction of genotype cross-reactive, hepatitis C virus-specific, cell-mediated immunity in DNA-vaccinated mice. J Virol. 92:e02133–17. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Castellanos M, Cinza Z, Dorta Z, Veliz G, Vega H, Lorenzo I, Ojeda S, Dueñas-Carrera S, Alvarez-Lajonchere L, Martínez G, et al: Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination. J Gene Med. 12:107–116. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Pierce BG, Boucher EN, Piepenbrink KH, Ejemel M, Rapp CA, Thomas WD Jr, Sundberg EJ, Weng Z and Wang Y: Structure-based design of hepatitis C virus vaccines that elicit neutralizing antibody responses to a conserved epitope. J Virol. 91:e01032–17. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cowton VM, Owsianka AM, Fadda V, Ortega-Prieto AM, Cole SJ, Potter JA, Skelton JK, Jeffrey N, Di Lorenzo C, Dorner M, et al: Development of a structural epitope mimic: An idiotypic approach to HCV vaccine design. NPJ Vaccines. 6(7)2021.PubMed/NCBI View Article : Google Scholar | |
|
Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han K, Berger K, Thudium K, Kuo C, et al: Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA. 91:1294–1298. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, Weiner AJ, Lau JY, Choo QL, et al: A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA. 93:1759–1763. 1996.PubMed/NCBI View Article : Google Scholar | |
|
Shi X, Cao F, Du Y, Hou L, Ji Y and Wang H: Protein expression and antigenicity detection of Hepatitis C virus envelope protein E2. Medical Journal of Chinese People's Liberation Army. 27:17–19. 2002. | |
|
Dai Z, Li G, Xu Q, Yao L, Han X, Yang L and Chen W: Expression and Identification of Hepatitis C Virus Envelop Protein E2. J Sun Yat-Sen Univ (Med Sci). 27:83–89. 2006.(In Chinese). | |
|
Earnest-Silveira L, Chua B, Chin R, Christiansen D, Johnson D, Herrmann S, Ralph SA, Vercauteren K, Mesalam A, Meuleman P, et al: Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line. J Gen Virol. 97:1865–1876. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Earnest-Silveira L, Christiansen D, Herrmann S, Ralph SA, Das V, Gowans EJ and Torres J: Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine. J Virol Methods. 236:87–92. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Shu F, Lei YF, Lin F, Wang X, Li B, Zhang LJ, Dong K, Zhang HZ and Wei SH: Construction of eukaryotic expression vector for chimeric gene of hepatitis C virus neutralizing epitopes with hepatitis B virus S antigen and its expression in 293T cells. Chinese Journal of Biologicals. 26:795–799. 2013. | |
|
Martínez-Donato G, Capdesuñer Y, Acosta-Rivero N, Rodríguez A, Morales-Grillo J, Martínez E, González M, Alvarez-Obregon JC and Dueñas-Carrera S: Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice. Mol Biotechnol. 35:225–235. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Yagnik AT, Lahm A, Meola A, Roccasecca RM, Ercole BB, Nicosia A and Tramontano A: A model for the hepatitis C virus envelope glycoprotein E2. Proteins. 40:355–366. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Duvet S, Cocquerel L, Pillez A, Cacan R, Verbert A, Moradpour D, Eychoeski C and Dubuisson J: Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem. 273:32088–32095. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Nemchinov LG, Liang TJ, Rifaat MM, Mazyad HM, Hadidi A and Keith JM: Development of a plant-derived subunit vaccine candidate against hepatitis C virus. Arch Virol. 145:2557–2573. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Bolhassani A, Davoudi N, Motevalli F and Agi E: Comparison of HCV Core and CoreE1E2 virus-like particles generated by stably transfected leishmania tarentolae for the Stimulation of Th1 immune responses in mice. Curr Drug Deliv. 14:1040–1049. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Kunkel M, Lorinczi M, Rijnbrand R, Lemon SM and Watowich SJ: Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein. J Virol. 75:2119–2129. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Tarr AW, Backx M, Hamed MR, Urbanowicz RA, McClure CP, Brown RJP and Ball JK: Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. Antivir Res. 160:25–37. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Cao L, Yu B, Kong D, Cong Q, Yu T, Chen Z, Hu Z, Chang H, Zhong J, Baker D and He Y: Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus. PLoS Pathog. 15(e1007759)2019.PubMed/NCBI View Article : Google Scholar | |
|
Fazlalipour M, Keyvani H, Monavari SH and Mollaie HR: Expression, purification and immunogenic description of a hepatitis C virus recombinant CoreE1E2 protein expressed by yeast Pichia pastoris. Jundishapur J Microbiol. 8(e17157)2015.PubMed/NCBI View Article : Google Scholar | |
|
Pechelyulko A, Andreeva-Kovalevskaya Z, Dmitriev D, Lavrov V, Massino Y, Nagel A, Segal O, Sokolova OS, Solonin A, Tarakanova Y and Dmitriev A: A simple method to purify recombinant HCV core protein expressed in Pichia pastoris for obtaining virus-like particles and producing monoclonal antibodies. Protein Expr Purif. 183(105864)2021.PubMed/NCBI View Article : Google Scholar | |
|
Cai W, Su L, Liao Q, Ye L, Wu Y, Wu Z and She Y: Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast. Antivir Res. 88:80–85. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Martinez-Donato G, Acosta-Rivero N, Morales-Grillo J, Musacchio A, Vina A, Alvarez C, Figueroa N, Guerra I, Garcia J, Varas L, et al: Expression and processing of hepatitis C virus structural proteins in Pichia pastoris yeast. Biochem Biophys Res Commun. 342:625–631. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Yao M, Fang H, Yin W, Lei Y, Yang J, Sun M, Tian J and Lv X: Prokaryotic expression and purification of truncated Hepatitis C Virus envelope glycoprotein E2. Science Technology and Engineering,. 9:2296–2303. 2009. | |
|
Cocquerel L, Meunier JC, Pillez A, Wychowski C and Dubuisson J: A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol. 72:2183–2191. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Cocquerel L, Wychowski C, Minner F, Penin F and Dubuisson J: Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. J Virol. 74:3623–3633. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Matsuura Y, Suzuki T, Suzuki R, Sato M, Aizaki H, Saito I and Miyamura T: Processing of E1 and E2 glycoproteins of hepatitis C virus expressed in mammalian and insect cells. Virology. 205:141–150. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Mizushima H, Hijikata M, Asabe S, Hirota M, Kimura K and Shimotohno K: Two hepatitis C virus glycoprotein E2 products with different C termini. J Virol. 68:6215–6222. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB, et al: Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog. 8(e1002895)2012.PubMed/NCBI View Article : Google Scholar | |
|
Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, et al: A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science. 349:1301–1306. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kulp DW, Steichen JM, Pauthner M, Hu X, Schiffner T, Liguori A, Cottrell CA, Havenar-Daughton C, Ozorowski G, Georgeson E, et al: Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat Commun. 8(1655)2017.PubMed/NCBI View Article : Google Scholar |
